# Vertex Therapeutics (VRTX) - Investment Analysis

## Recommendation: BUY

**Price Target:** $480
**Current Price:** $425
**Upside:** 13%

## Investment Thesis

Vertex represents an attractive risk/reward into the VX-548 Phase 3 readout. The company's dominant cystic fibrosis franchise provides significant downside protection, while success in the pain program would unlock substantial upside. We estimate a 55% probability of positive Phase 3 results.

## Key Supporting Points

1. **CF Franchise Provides Floor:** Vertex's CF business generates over $9B in annual revenue with 40%+ operating margins. This alone supports a stock price of approximately $380-400.

2. **Asymmetric Risk/Reward:** With limited downside (~6%) and significant upside potential (30%+), the risk/reward skews favorably for longs.

3. **Phase 2 Data Encouraging:** The bunionectomy trial showed highly significant results (p<0.001), suggesting the mechanism is valid for acute pain.

## Valuation

At 11x forward earnings, VRTX trades at a discount to its 5-year average of 14x. The CF business alone justifies current levels, meaning investors get the pain option for free.

## Key Risks

- **Clinical Failure (40% probability):** Phase 3 could miss its primary endpoint, though downside is protected by CF value
- **Commercial Execution:** Even if approved, peak sales depend on physician adoption and payer coverage
- **Competitive Threats:** Other companies are developing non-opioid pain treatments

## Position Sizing

Recommend 2-3% position given binary catalyst nature. Willing to add on weakness to $400-410.

## Catalysts

- Q1 2025: VX-548 Phase 3 readout (primary catalyst)
- Q2 2025: Potential NDA filing if positive
- Ongoing: CF quarterly results

## Sources

- Vertex 10-K 2023
- Vertex Q3 2024 Earnings Call
- R&D Day Presentation September 2024
